South African Breakthrough! SAHPRA Announces Controlled Compassionate Access to Ivermectin

South African Breakthrough! SAHPRA Announces Controlled Compassionate Access to Ivermectin

The South African Health Products Regulatory Authority (SAHPRA) has stepped up in a big way, announcing the regulatory agency would now allow for controlled compassionate use of Ivermectin as an off-label treatment for COVID-19. These access protocols will be shared within days, reports the agency. Announcing the decision along with the National Press Club today, TrialSite commends the agency for its flexibility and consideration as to the accumulating evidence combined with troubling trends with SARS-CoV-2. Although the regulatory agency still won’t accept the evidentiary arguments based on existing meta-analyses produced by groups, such as the Front Line COVID-19 Critical Care Alliance (FLCCC), Dr. Andrew Hill with the University of Liverpool or Tess Lawrie with the Evidence-Based Medicine Consultancy, the agency's action benefits humanity there.

Not a Changed Position..But

Although the drug regulatory body is exhibiting flexibility for compassionate use, they are adamant that the fundamental position as to lack of evidence hasn’t changed. That is according to Dr. Boitumelo Semete -Makokotlela, chief executive of SAHPRA, that “This does not mean that our position changes a...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee